B+
Bull case
20%
Probability
Target price
$264.73
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
ABBV
AbbVieDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$227.23
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$185.31
Analysis reference price unavailable
Analysis 2025-09-27 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-09-27
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.8
Score
AI commentary
Market tone is mildly positive: analysts skew buy and median targets sit modestly above the current trade. Investors are focused on new-product execution and the durability of dividend/buyback returns; consensus upside exists but is limited. Recent price action reflects dividend support alongside cautious positioning ahead of pipeline readouts.
RankAlpha Sentiment AI - 2025-09-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventQuarterly earnings / guidance updateMedium impact
Q3/Q4 results and management guidance can move the stock; market watches margins and guidance post-Rinvoq/Skyrizi mix [#YahooFinance].
-catalystDividend policy & capital allocation newsMedium impact
Dividend increases or buyback changes typically support the price but are largely anticipated given high payout; surprises can still move the stock [#YahooFinance].
-catalystOncology and late-stage readouts / launchesHigh impact
AbbVie's oncology launches (e.g., Elahere, Epkinly) and registrational readouts could re-rate growth expectations if positive [#YahooFinance].
Recommendation
N/A
No formal recommendation provided.
As of 2025-09-27 • Updated nightlySource: Internal modelMethodology